[PRESS RELEASE] – LONDON, May 15, 2025 – Curaleaf International, part of Curaleaf Holdings Inc., a leading international provider of medical cannabis products, announced the launch of Curaleaf-branded products in Australia. This announcement marks the expansion of Curaleaf's presence in one of the world's fastest-growing medical cannabis markets and underscores its commitment to local collaboration, clinical integrity and patient care.
The initial product offering, comprising four cannabis flower strains, will be distributed via Canngea, a licensed Australian manufacturer and wholesaler with a wealth of experience in medical cannabis. This partnership supports Curaleaf's vision to be the world's leading cannabis company by consistently delivering superior products and services.
Over the coming months, patients and health care professionals in Australia can look forward to a broader portfolio and further innovative solutions offered by Curaleaf, including precision-dosed inhalation formats and popular strains already widely prescribed across the U.K., Germany and other key European markets.
"Entering the Australian market is a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines,” Juan Martinez, head of Curaleaf International, said. “We're committed to supporting Australian patients and health care professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains."
Curaleaf Chairman and CEO Boris Jordan said: "Australia is an exciting and rapidly evolving market, expected to surpass $1 billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis. We're bringing a proven portfolio and a strong track record of innovation, with more to come."
